Abstract:Aleksandr Kakinen, 1, 2 Yuhao Jiang, 2 Thomas Paul Davis, 2 Tambet Teesalu, 3, 4 Mart Saarma 1 1 Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland; 2 Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, QLD, Australia; 3 Institute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia; 4 Materials Research Laboratory, University of California Santa Barbara, Santa Barbara, CA, USA Correspondence: Mart Saarma, Institute of Biotechnology, HiLIFE, University of Helsinki, Viikinkaari 5D, Helsinki, 00790, Finland, Tel +358505002726 ; +358294159378, Email Aleksandr Kakinen, Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Building 75, Cnr College Road& Cooper Road, St Lucia, QLD, 4067, Australia, Tel +61 7 344 63152, Email Brain diseases are the most devastating problem among the world's increasingly aging population, and the number of patients with neurological diseases is expected to increase in the future. Although methods for delivering drugs to the brain have advanced significantly, none of these approaches provide satisfactory results for the treatment of brain diseases. This remains a challenge due to the unique anatomy and physiology of the brain, including tight regulation and limited access of substances across the blood-brain barrier. Nanoparticles are considered an ideal drug delivery system to hard-to-reach organs such as the brain. The development of new drugs and new nanomaterial-based brain treatments has opened various opportunities for scientists to develop brain-specific delivery systems that could improve treatment outcomes for patients with brain disorders such as Alzheimer's disease, Parkinson's disease, stroke and brain tumors. In this review, we discuss noteworthy literature that examines recent developments in brain-targeted nanomedicines used in the treatment of neurological diseases. Keywords: brain delivery, blood-brain barrier, targeted delivery, nanoparticle, neurodegenerative diseases, stroke, cancer In 1885, Paul Ehrlich made a groundbreaking discovery: intravenous injection of dyes stained all organs except the brain. 1 This discovery illuminated the existence of the highly restrictive biological barrier in the central nervous system (CNS) known as the blood-brain barrier (BBB). 2 The BBB is essential for protecting the CNS from toxins, drugs, and pathogens. Most of the BBB surface consists of thin capillaries in which tight BBB connections occur between endothelial cells, preventing chemicals from entering the brain paracellularly. 3 In addition to endothelial cells, brain cells such as pericytes and astrocytes build and maintain the BBB. The BBB can only be penetrated passively by lipid-soluble solutes that can readily diffuse across the capillary endothelial membrane. 4 As a result, about 98% of small molecules, virtually all large molecules and most biological drugs are excluded from the BBB. 5 The integrity of the BBB is critical for the proper functioning of the CNS. Conversely, disruption of the BBB is a key element in the development of many brain disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), stroke and several others. 6–9 As the world population ages, the global burden associated with neurological disorders increases worldwide, accounting for more than 6% of all diseases 10 and costing more than US$1.7 trillion annually in the US and Europe alone. 11,12 In recent years, CNS diseases have become a leading cause of disability-adjusted life years and one of the most common causes of death and disability in the world. 13 Over the past 30 years, neurological diseases have increased disability-adjusted life years and mortality by 15% and 39%, respectively. 14 The number of people with dementia is estimated to increase from ~57 million cases worldwide in 2019 to 152 million cases in 2050. 15 AD, PD, stroke, multiple sclerosis and amyotrophic lateral sclerosis (ALS) are just some of the incurable CNS diseases. Most available medications only relieve symptoms and do not affect the progression of the disease. Thus, there is an urgent need for more effective drug delivery methods and disease-modifying drugs that can slow down or stop neurodegeneration and cure neurological disorders. The goal is to stop neurodegeneration and regenerate still alive neurons. Drug delivery to the CNS remains a major therapeutic challenge. Delivery of therapeutics across the BBB is considered a minimally invasive strategy to target the brain. However, most preclinical and clinical studies to date sho -Abstract Truncated-

Kinase Targets in Cns Drug Discovery

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Irreversible Kinase Inhibitors Targeting Cysteine Residues and their Applications in Cancer Therapy

Kinase inhibitors: 20 years of success and many new challenges and recent trends in their patents

Empirical Analysis of Drug Targets for Nervous System Disorders

The Prospect of Substrate-Based Kinase Inhibitors to Improve Target Selectivity and Overcome Drug Resistance.

The Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway as a Discovery Target in Stroke

Targeting cancer with small molecule kinase inhibitors

Kinase-targeted cancer therapies: progress, challenges and future directions

Trends in kinase drug discovery: targets, indications and inhibitor design

Small Molecule Substrate Phosphorylation Site Inhibitors of Protein Kinases: Approaches and Challenges

Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?

Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior

Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?

Brain Targeting Nanomedicines: Pitfalls and Promise

Identification of inhibitors for neurodegenerative diseases targeting dual leucine zipper kinase through virtual screening and molecular dynamics simulations

Utilizing Multifaceted Approaches to Target Drug Delivery in the Brain: From Nanoparticles to Biological Therapies

In Silico Enabled Discovery of KAI-11101, a Preclinical DLK Inhibitor for the Treatment of Neurodegenerative Disease and Neuronal Injury

Phenotypic approaches for CNS drugs

Kinase Inhibitors FDA-Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities

Identification of potential inhibitors of tropomyosin receptor kinase B targeting CNS-related disorders and cancers